Breaking News

bioRASI Acquires Sponsors Clinical Research Group

March 27, 2013

Expands Eastern European presence

bioRASI has acquired Sponsors Clinical Research Group, LLC (SCRG), a Ukrainian based regulatory and clinical CRO. SCRG, established in 2004, conducts clinical studies in a range of therapeutic areas, including cardiology, neurology, oncology, endocrinology and pulmonology.
 
"We have been working with SCRG for over a year and have been impressed with the superior expertise of its staff, so it was only natural to consider a more integrated structure," said Dr. Boris Reznik, chairman of bioRASI. "This acquisition enhances bioRASI's global infrastructure focused on delivering optimized clinical development for our sponsors who are under increasing pressure to accelerate drug development timelines while minimizing costs." 
 
"While SCRG has been working for many global sponsors and CROs, we have never experienced the powers of project management comparable to that of bioRASI," said Dr. Veklych, SCRG's executive director. "An integrated set of tools embodied in the bioRASI Process Infrastructure (BPI) greatly enhances optimized project delivery capabilities. We are excited about being a part of bioRASI's winning team."

Related Compliance:

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus

  • Choosing Oral Formulations for First-in-man Clinical Trials

    Choosing Oral Formulations for First-in-man Clinical Trials

    Jon Sutch, Senior Manager of Formulation Development, Patheon||October 11, 2016
    Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems